BIVI
BioVie Inc.
Biotechnology
Market Cap$2M
5Y Perf.-99.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BIVI vs ATHA
Revenue, margins, valuation, and 5-year total return — side by side.
ATHA
Athira Pharma, Inc.
Biotechnology
Market Cap$17M
5Y Perf.-97.4%
BIVI vs ATHA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BIVI | ATHA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $2M | $17M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-17M | $-129M |
| Total Debt | $350K | $803K |
| Cash & Equiv. | $18M | $69M |
BIVI vs ATHA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BIVI
ATHA
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| BioVie Inc. (BIVI) | 100 | 0.2 | -99.8% |
| Athira Pharma, Inc. (ATHA) | 100 | 2.6 | -97.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BIVI vs ATHA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BIVI and ATHA are tied at the top with 2 categories each — the right choice depends on your priorities. Athira Pharma, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
BIVI
BioVie Inc.
The Growth Play
BIVI has the current edge in this matchup, primarily because of its strength in growth exposure and sleep-well-at-night.
- EPS growth 83.4%
- Lower volatility, beta 1.41, Low D/E 1.8%, current ratio 9.10x
- 28.3% revenue growth vs ATHA's -64.6%
Best for: growth exposure and sleep-well-at-night
ATHA
Athira Pharma, Inc.
The Income Pick
ATHA is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.38
- -97.5% 10Y total return vs BIVI's -99.3%
- Beta 1.38, current ratio 1.88x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BIVI | 28.3% revenue growth vs ATHA's -64.6% |
| Stability / Safety | ATHA | Beta 1.38 vs BIVI's 1.41 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ATHA | +62.5% vs BIVI's -87.8% |
| Efficiency (ROA) | BIVI | -77.7% ROA vs ATHA's -225.7% |
BIVI vs ATHA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBIVILAGGINGATHA
ATHAAthira Pharma, Inc.
2leads
BIVIBioVie Inc.
2leads
6 Total Categories
CATEGORYLEADERvs ATHAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BIVI1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BIVI6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
ATHA5/6
Risk & VolatilityBeta, volatility, and downside exposure
ATHA2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BIVI leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
BIVI and ATHA operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | BIVIBioVie Inc. | ATHAAthira Pharma, In… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$18M | -$110M |
| Net IncomeAfter-tax profit | -$17M | -$129M |
| Free Cash FlowCash after capex | -$14M | -$52M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +83.3% | +24.8% |
BIVI leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — BIVI and ATHA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | BIVIBioVie Inc. | ATHAAthira Pharma, In… |
|---|---|---|
| Market CapShares × price | $2M | $17M |
| Enterprise ValueMkt cap + debt − cash | -$15M | -$30M |
| Trailing P/EPrice ÷ TTM EPS | -0.12x | -0.17x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.12x | 0.37x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — BIVI and ATHA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
BIVI leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
BIVI delivers a -90.7% return on equity — every $100 of shareholder capital generates $-91 in annual profit, vs $-4 for ATHA. BIVI carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ATHA's 0.03x. On the Piotroski fundamental quality scale (0–9), BIVI scores 3/9 vs ATHA's 2/9, reflecting mixed financial health.
| Metric | BIVIBioVie Inc. | ATHAAthira Pharma, In… |
|---|---|---|
| ROE (TTM)Return on equity | -90.7% | -3.8% |
| ROA (TTM)Return on assets | -77.7% | -2.3% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -102.8% | -2.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 0.03x |
| Net DebtTotal debt minus cash | -$17M | -$68M |
| Cash & Equiv.Liquid assets | $18M | $69M |
| Total DebtShort + long-term debt | $349,894 | $803,000 |
| Interest CoverageEBIT ÷ Interest expense | -984.01x | — |
BIVI leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
ATHA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ATHA five years ago would be worth $234 today (with dividends reinvested), compared to $10 for BIVI. Over the past 12 months, ATHA leads with a +62.5% total return vs BIVI's -87.8%. The 3-year compound annual growth rate (CAGR) favors ATHA at -46.7% vs BIVI's -87.8% — a key indicator of consistent wealth creation.
| Metric | BIVIBioVie Inc. | ATHAAthira Pharma, In… |
|---|---|---|
| YTD ReturnYear-to-date | +12.8% | -37.6% |
| 1-Year ReturnPast 12 months | -87.8% | +62.5% |
| 3-Year ReturnCumulative with dividends | -99.8% | -84.8% |
| 5-Year ReturnCumulative with dividends | -99.9% | -97.7% |
| 10-Year ReturnCumulative with dividends | -99.3% | -97.5% |
| CAGR (3Y)Annualised 3-year return | -87.8% | -46.7% |
ATHA leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
ATHA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ATHA is the less volatile stock with a 1.38 beta — it tends to amplify market swings less than BIVI's 1.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATHA currently trades 51.9% from its 52-week high vs BIVI's 12.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BIVIBioVie Inc. | ATHAAthira Pharma, In… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.41x | 1.38x |
| 52-Week HighHighest price in past year | $12.40 | $8.36 |
| 52-Week LowLowest price in past year | $1.06 | $2.34 |
| % of 52W HighCurrent price vs 52-week peak | +12.1% | +51.9% |
| RSI (14)Momentum oscillator 0–100 | 50.5 | 38.4 |
| Avg Volume (50D)Average daily shares traded | 74K | 46K |
ATHA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | BIVIBioVie Inc. | ATHAAthira Pharma, In… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
BIVI leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ATHA leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallBioVie Inc. (BIVI)Leads 2 of 6 categories
Loading custom metrics...
BIVI vs ATHA: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — BIVI or ATHA?
Over the past 5 years, Athira Pharma, Inc.
(ATHA) delivered a total return of -97. 7%, compared to -99. 9% for BioVie Inc. (BIVI). Over 10 years, the gap is even starker: ATHA returned -97. 5% versus BIVI's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — BIVI or ATHA?
By beta (market sensitivity over 5 years), Athira Pharma, Inc.
(ATHA) is the lower-risk stock at 1. 38β versus BioVie Inc. 's 1. 41β — meaning BIVI is approximately 2% more volatile than ATHA relative to the S&P 500. On balance sheet safety, BioVie Inc. (BIVI) carries a lower debt/equity ratio of 2% versus 3% for Athira Pharma, Inc. — giving it more financial flexibility in a downturn.
03Which is growing faster — BIVI or ATHA?
On earnings-per-share growth, the picture is similar: BioVie Inc.
grew EPS 83. 4% year-over-year, compared to 2. 0% for Athira Pharma, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — BIVI or ATHA?
BioVie Inc.
(BIVI) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Athira Pharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BIVI leads at 0. 0% versus 0. 0% for ATHA. At the gross margin level — before operating expenses — BIVI leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — BIVI or ATHA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is BIVI or ATHA better for a retirement portfolio?
For long-horizon retirement investors, Athira Pharma, Inc.
(ATHA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (ATHA: -97. 5%, BIVI: -99. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between BIVI and ATHA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.